Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibodies armed with B-BiTEs
This episode covers a long-term study on FCR therapy for CLL, the role of genetic alterations and minimal residual disease in adult ALL, and a pre-clinical look at bispecific antibody immunotherapy for myeloma.